Veru confirms sabizabulin findings with Phase III study

9 August 2022

Miami, USA-based Veru (Nasdaq: VERU) has presented Phase III results on sabizabulin in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) at the International Conference on Emerging Infectious Diseases.

Sabizabulin is an oral, novel microtubule disruptor that has dual antiviral and anti-inflammatory activity. A 9mg dose was compared in the trial to placebo in 204 hospitalized moderate to severe COVID-19 patients who were at high risk for ARDS and death.

"We have scaled up manufacturing to meet the demands of this summer’s COVID-19 surge as well as the seasonal surges that are expected in fall and winter"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK